The magnesium ion is an essential cation in the human body and participates in numerous physiological activities. A deficiency in magnesium ions is closely associated with tumor development, and supplementation with magnesium ions has been shown to partially inhibit tumor growth. However, the specific mechanisms by which magnesium ions suppress tumor proliferation remain unclear. Currently, studies have revealed that mitochondria may serve as a crucial intermediate link in the regulation of tumors by magnesium ions. Mitochondria might intervene in the proliferation and invasion of tumor cells by modulating energy metabolism and oxidative stress levels. Regrettably, there has been no comprehensive review of the role of magnesium in cancer therapy to date. Therefore, this article provides a comprehensive scrutiny of the relationship between magnesium ions and tumors, aiming to offer insights for clinical tumor treatment strategies involving magnesium ion intervention.

This study investigates the protective effects of magnesium sulfate on dopamine neurons in the retinas of rats with 6-hydroxydopamine (6-OHDA)-induced Parkinson’s disease (PD). Rapidly progressing cognitive decline often precedes or coincides with the motor symptoms associated with PD. PD patients also frequently exhibit visual function abnormalities. However, the specific mechanisms underlying visual dysfunction in PD patients are not yet fully understood. Therefore, this study aims to investigate whether magnesium homeostasis affects dopaminergic neurons in the retina of PD rats. Thirty-six rats were divided into four groups: (1) control, (2) control with magnesium sulfate (control/MgSO₄), (3) Parkinson’s disease (PD), and (4) Parkinson’s disease with magnesium sulfate (PD/MgSO₄). The apomorphine-induced (APO) rotation test assessed the success of the PD models. The open-field experiment measured the rats’ anxiety levels. Tyrosine hydroxylase (TH) and glutamate levels, indicators of dopamine neuron survival, were detected using immunofluorescence staining. Protein levels of solute carrier family 41 A1 (SCL41A1), magnesium transporter 1 (MagT1), and cyclin M2 (CNNM2) in the retina were analyzed using Western blot. Results showed that, compared to the PD group, rats in the PD/MgSO₄ group had improved psychological states and motor performance at two and four weeks post-surgery. The PD/MgSO₄ group also exhibited significantly higher TH fluorescence intensity in the left retinas and lower glutamate fluorescence intensity than the PD group. Additional experiments indicated that the protein levels of SLC41A1, MagT1, and CNNM2 were generally higher in the retinas of the PD/MgSO₄ group, along with an increase in retinal magnesium ion content. This suggests that magnesium sulfate may reduce glutamate levels and protect dopamine neurons in the retina. Thus, magnesium sulfate might have therapeutic potential for visual functional impairments in PD patients.

The magnesium ion is an essential cation in the human body and participates in numerous physiological activities. A deficiency in magnesium ions is closely associated with tumor development, and supplementation with magnesium ions has been shown to partially inhibit tumor growth. However, the specific mechanisms by which magnesium ions suppress tumor proliferation remain unclear. Currently, studies have revealed that mitochondria may serve as a crucial intermediate link in the regulation of tumors by magnesium ions. Mitochondria might intervene in the proliferation and invasion of tumor cells by modulating energy metabolism and oxidative stress levels. Therefore, this article provides a comprehensive review of the relationship between magnesium ions and tumors, the mechanisms by which magnesium ions regulate mitochondrial function, and the theoretical basis and prospects of magnesium ion regulation of mitochondrial function for tumor treatment. This review aims to offer insights for clinical tumor treatment strategies involving magnesium ion intervention.

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. The main pathological features of PD are the degeneration and death of dopamine neurons in the substantia nigra-striatal pathway and the accumulation of Lewy bodies in neurons. In addition to the well-known hallmark symptoms such as resting tremor and muscle rigidity, Parkinson's patients also experience non-motor symptoms such as visual disturbances, hyposmia, and sleep disturbances. At the same time, visual disturbances appear earlier than motor symptoms. The visual dysfunction in early-stage of Parkinson's disease indicates the occurrence and development of the disease. The visual dysfunction in Parkinson's disease is due to the damage of retinal dopamine neurons. This study found that magnesium sulfate supplementation can effectively delay the death of retinal dopamine neurons in 6-OHDA induced rat model of PD and improve the motor symptoms of rats with anxiety-like behavior. Therefore, magnesium sulfate may provide a new option for the early diagnosis and treatment of Parkinson's disease.

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. The main pathological features of PD are the degeneration and death of dopamine neurons in the substantia nigra-striatal pathway and the accumulation of Lewy bodies in neurons. In addition to the well-known hallmark symptoms such as resting tremor and muscle rigidity, Parkinson's patients also experience non-motor symptoms such as visual disturbances, hyposmia, and sleep disturbances. At the same time, visual disturbances appear earlier than motor symptoms. The visual dysfunction in early-stage of Parkinson's disease indicates the occurrence and development of the disease. The visual dysfunction in Parkinson's disease is due to the damage of retinal dopamine neurons. This study found that magnesium sulfate supplementation can effectively delay the death of retinal dopamine neurons in 6-OHDA induced rat model of PD and improve the motor symptoms of rats with anxiety-like behavior. Therefore, magnesium sulfate may provide a new option for the early diagnosis and treatment of Parkinson's disease.